4-{4-[3-(Trifluoromethyl)phenyl]-1,3-thiazolidin-2-yl}benzoic acid | 321430-15-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{4-[3-(Trifluoromethyl)phenyl]-1,3-thiazolidin-2-yl}benzoic acid
• 英文别名: 4-[4-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-2-yl]benzoic acid
• CAS: 321430-15-3
• 化学式: C₁₇H₁₄F₃NO₂S
• 分子量: 353.4
• InChiKey: FSEDNUNNCKBLMC-UHFFFAOYSA-N

物化性质

• 沸点：
  509.2±60.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
  申请人：Syros Pharmaceuticals, Inc.

  公开号：US10240210B2

  公开（公告）日：2019-03-26

  Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.

  本文描述的方法可确定对 RARA 激动剂敏感的细胞群，并识别将从 RARA 激动剂治疗中获益的患者群。这些方法可包括向患者群施用 RARA 激动剂。
• METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS
  申请人：SYROS PHARMACEUTICALS, INC.

  公开号：US20160355888A1

  公开（公告）日：2016-12-08

  The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.
• US9845508B2
  申请人：——

  公开号：US9845508B2

  公开（公告）日：2017-12-19
• [EN] METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-α AGONISTS<br/>[FR] PROCÉDÉS DE STRATIFICATION DE PATIENTS POUR UN TRAITEMENT AU MOYEN D'AGONISTES DU RÉCEPTEUR Α DE L'ACIDE RÉTINOÏQUE
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2016161107A1

  公开（公告）日：2016-10-06

  The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.
• [EN] METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-ALPHA AGONIST AND AN ANTI-CD38 ANTIBODY<br/>[FR] MÉTHODES DE TRAITEMENT DE PATIENTS À L'AIDE D'UN AGONISTE DU RÉCEPTEUR ALPHA DE L'ACIDE RÉTINOÏQUE ET D'UN ANTICORPS ANTI-CD38
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2018067946A1

  公开（公告）日：2018-04-12

  The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists in combination with another therapy, more specifically an anti-CD38 therapy. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such combination therapy is suitable for use in treatment.